

SAFETY DATA SHEET

SECTION 1 : IDENTIFICATION

Product Name: **Famotidine Injection**
Manufacturer Name: Fresenius Kabi USA, LLC
Address: Three Corporate Drive
 Lake Zurich, Illinois 60047
General Phone Number: (847) 550-2300
Customer Service Phone Number: (888) 386-1300
Health Issues Information: (800) 551-7176
SDS Creation Date: January 08, 2009
SDS Revision Date: June 01, 2015
(M)SDS Format:

SECTION 2 : HAZARD(S) IDENTIFICATION

GHS Pictograms:



Signal Word: DANGER.

GHS Class: Respiratory sensitisation. Category 1.
 Skin Sensitization. Category 1.
 Reproductive toxicity. Effects on or via lactation.

Hazard Statements: May cause allergy or asthma symptoms or breathing difficulties if inhaled.
 May cause an allergic skin reaction.
 May cause harm to breast-fed children.

Precautionary Statements: Obtain special instructions before use.
 Do not breathe dust/fume/gas/mist/vapours/spray.
 Avoid breathing dust/fume/gas/mist/vapours/spray.
 Avoid contact during pregnancy and while nursing.
 Wash hands thoroughly after handling.
 Do not eat, drink or smoke when using this product.
 Contaminated work clothing should not be allowed out of the workplace.
 Wear protective gloves/protective clothing/eye protection/face protection.
 In case of inadequate ventilation wear respiratory protection.
 IF ON SKIN: Wash with plenty of water.
 IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing.
 IF exposed or concerned: Get medical advice/attention.
 Specific treatment (see ... on this label).
 If skin irritation or rash occurs: Get medical advice/attention.
 If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician.
 Take off contaminated clothing and wash it before reuse.
 Dispose of contents/container in accordance with Local, State, Federal and Provincial regulations.

Emergency Overview: This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.

Route of Exposure: Inhalation Ingestion Eye contact Skin Absorption. Injection.

Potential Health Effects:

Eye: Contact with eyes may cause irritation.

Skin: May cause skin irritation.

Inhalation: May cause irritation of respiratory tract.

Ingestion: May cause irritation.

Signs/Symptoms: Potential adverse reactions from prescribed doses and overdoses are described in the package insert.
 Adverse reactions from therapeutic doses include: headache, dizziness, constipation and diarrhea.
 There is no experience to date with deliberate overdosage. Occupational exposure has not been fully investigated.

Aggravation of Pre-Existing Conditions: Individuals with hypersensitivity to any component of this product. Cross sensitivity in this class of compounds has been observed. Therefore, individuals with a history of hypersensitivity to other H2-receptor antagonists should avoid contact with this product.

SECTION 3 : COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS#	Ingredient Percent	EC Num.
Famotidine	76824-35-6	10 mg/mL	
L-Aspartic Acid	56-84-8	4 mg/mL	

Benzyl Alcohol	100-51-6	0.9 %
Mannitol	69-65-8	20 mg/mL
Water for Injection	7732-18-5	Quantity Sufficient

SECTION 4 : FIRST AID MEASURES

Eye Contact:	Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of the eyes by separating the eyelids with fingers. Get immediate medical attention.
Skin Contact:	Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing contaminated clothing and shoes. Get medical attention if irritation develops or persists.
Inhalation:	If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained personnel. Seek immediate medical attention.
Ingestion:	If conscious, flush mouth out with water immediately. Call a physician or poison control center immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person.
Other First Aid:	For Adverse Event Information, please call (800) 551-7176.

SECTION 5 : FIRE FIGHTING MEASURES

Flash Point:	Not established.
Flash Point Method:	Not established.
Auto Ignition Temperature:	Not established.
Lower Flammable/Explosive Limit:	Not established.
Upper Flammable/Explosive Limit:	Not established.
Fire Fighting Instructions:	Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible, contain fire run-off water.
Extinguishing Media:	Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires involving this material. Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Protective Equipment:	As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent) and full protective gear.
Hazardous Combustion Byproducts:	Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of combustion.

SECTION 6 : ACCIDENTAL RELEASE MEASURES

Personnel Precautions:	Evacuate area and keep unnecessary and unprotected personnel from entering the spill area. Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as listed in section 8.
Environmental Precautions:	Avoid runoff into storm sewers, ditches, and waterways.
Methods for containment:	Contain spills with an inert absorbent material such as soil, sand or oil dry.
Methods for cleanup:	Absorb spill with inert material (e.g., dry sand or earth), then place in a chemical waste container. After removal, flush spill area with soap and water to remove trace residue.

SECTION 7 : HANDLING and STORAGE

Handling:	When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes. Use with adequate ventilation. Use only in accordance with directions.
Storage:	Store at refrigerated temperatures 2 to 8°C (36 to 46°F).
Work Practices:	Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower.
Hygiene Practices:	Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist.

SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

Engineering Controls:	General ventilation is sufficient if this product is being used in a controlled medical setting (clinic, hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended exposure limits.
Eye/Face Protection:	Chemical splash goggles. Wear a face shield also when splash hazard exist.

Skin Protection Description:	Protective laboratory coat, apron, or disposable garment recommended.
Hand Protection Description:	Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data. Nitrile rubber or natural rubber gloves are recommended.
Respiratory Protection:	No personal respiratory protective equipment is normally required when this product is being used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site (http://www.cdc.gov/niosh/npptl/topics/respirators/) for a list of respirator types and approved suppliers.
Other Protective:	Consult with local procedures for selection, training, inspection and maintenance of the personal protective equipment.

EXPOSURE GUIDELINES

SECTION 9 : PHYSICAL and CHEMICAL PROPERTIES

Physical State:	Liquid solution.
Color:	Colorless.
Odor:	Odorless.
Boiling Point:	Not established.
Melting Point:	Not established.
Solubility:	Freely soluble in glacial acetic acid, slightly soluble in methanol, very slightly soluble in water, and practically insoluble in ethanol.
Vapor Density:	Not established.
Vapor Pressure:	Not established.
Percent Volatile:	Not established.
pH:	5.0 - 5.7
Molecular Formula:	Mixture
Molecular Weight:	337.45
Flash Point:	Not established.
Flash Point Method:	Not established.
Auto Ignition Temperature:	Not established.

SECTION 10 : STABILITY and REACTIVITY

Chemical Stability:	Stable under normal temperatures and pressures.
Hazardous Polymerization:	Not reported.
Conditions to Avoid:	No conditions contributing to instability are known to exist for normal handling of this product.

SECTION 11 : TOXICOLOGICAL INFORMATION

Acute Toxicity:	Eye, skin, and respiratory irritation may occur.
<u>Famotidine :</u>	
Acute Toxicity:	LD50 IP: Rat 800 mg/kg LD50 SC: Rat 800 mg/kg LD50 IV: Rat 204 mg/kg LD50 SC: Mouse 41 mg/kg LD50 IP: Mouse 778 mg/kg LD50 SC: Mouse 800 mg/kg LD50 IV: Mouse 254 mg/kg
Acute Effects:	Eye, skin, and respiratory irritation may occur.
Chronic Effects:	None known.
<u>Famotidine :</u>	
RTECS Number:	UA2300000
Skin:	Administration onto the skin - Rabbit TDLo: 50 pph/10D (Intermittent) [Skin and Appendages - Primary irritation (After topical exposure) Nutritional and Gross Metabolic - Weight loss or decreased weight gain]
Ingestion:	Oral - Rat LD50: 4049 mg/kg [Details of toxic effects not reported other than lethal dose value] Oral - Mouse LD50: 4686 mg/kg [Details of toxic effects not reported other than lethal dose value]
Other Toxicological Information:	Intravenous. - Rat LD50: 204 mg/kg [Details of toxic effects not reported other than lethal dose value] Intravenous. - Mouse LD50: 254 mg/kg [Details of toxic effects not reported other than lethal dose value] Intravenous. - Rat TDLo: 5 mg/kg [Liver - other changes Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - multiple enzyme effects Biochemical - Metabolism (Intermediary) - effect on inflammation or mediation of inflammation] Intravenous. - Rat TDLo: 5 mg/kg [Vascular - measurement of regional blood flow Liver - liver function tests impaired Liver - other changes] Intravenous. - Rat TDLo: 18200 mg/kg/13W (intermittent) [Kidney/Ureter/Bladder - changes in tubules]

(including acute renal failure, acute tubular necrosis) Skin and Appendages - dermatitis, other (after systemic exposure) Related to Chronic Data - death]
Intravenous. - Rat TDLo: 2200 mg/kg [Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)]
Intravenous. - Rabbit TDLo: 130 mg/kg [Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)]
Subcutaneous - Rat LD50: 800 mg/kg [Details of toxic effects not reported other than lethal dose value]
Subcutaneous - Mouse LD50: 800 mg/kg [Details of toxic effects not reported other than lethal dose value]
Intraperitoneal. - Rat LD50: 800 mg/kg [Details of toxic effects not reported other than lethal dose value]
Intraperitoneal. - Mouse LD50: 778 mg/kg [Behavioral - somnolence (general depressed activity)
Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea]
Intraperitoneal. - Mouse LD50: >1500 mg/kg [Details of toxic effects not reported other than lethal dose value]
Intraperitoneal. - Rat TDLo: 4 mg/kg [Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - carbonic anhydrase]
Intraperitoneal. - Mouse TDLo: 75 mg/kg/15D (intermittent) [Brain and Coverings - other degenerative changes Biochemical - Neurotransmitters or modulators (putative) - dopamine at other sites]

L-Aspartic Acid :

RTECS Number: CI9098500

Other Toxicological Information: Intraperitoneal. - Mouse LD50 : 6 gm/kg [Details of toxic effects not reported other than lethal dose value]
Intraperitoneal. - Rat TDLo : 500 mg/kg [Behavioral - changes in motor activity (specific assay)]
Intraperitoneal. - Rat TDLo : 100 mg/kg [Behavioral - alteration of classical conditioning]
Intraperitoneal. - Rat TDLo : 10 mg/kg [Behavioral - alteration of operant conditioning]
Intraperitoneal. - Rat TDLo : 100 mg/kg/10D-I [Behavioral - alteration of classical conditioning]
Intraperitoneal. - Rat TDLo : 1000 mg/kg/10D-I [Behavioral - excitement Behavioral - alteration of classical conditioning]

Benzyl Alcohol:

RTECS Number: DN3150000

Skin: Administration onto the skin - Rabbit LD50: 2000 mg/kg [Details of toxic effects not reported other than lethal dose value]
Administration onto the skin - Rabbit Standard Draize test.: 100 mg/24H
Administration onto the skin - Rat LD50: 100 pph/90M [Details of toxic effects not reported other than lethal dose value]

Inhalation: Inhalation - Mouse LC50: >500 mg/m³ [Behavioral - Somnolence (general depressed activity)
Behavioral - Ataxia Lungs, Thorax, or Respiration - Respiratory depression]
Inhalation - Rat LC50: >500 mg/m³ [Behavioral - Somnolence (general depressed activity) Behavioral - Ataxia Lungs, Thorax, or Respiration - Respiratory depression]

Ingestion: Oral - Rat LD50: 1230 mg/kg [Behavioral - Somnolence (general depressed activity) Behavioral - Excitement Behavioral - Coma]
Oral - Mouse LD50: 1360 mg/kg [Details of toxic effects not reported other than lethal dose value]
Oral - Mouse LD50: 1360 mg/kg [Behavioral - Somnolence (general depressed activity) Behavioral - Ataxia Lungs, Thorax, or Respiration - Respiratory depression]
Oral - Rat LD50: 1660 mg/kg [Behavioral - Somnolence (general depressed activity) Behavioral - Ataxia Lungs, Thorax, or Respiration - Respiratory depression]
Oral - Rat LD50: 1.5 mL/kg [Details of toxic effects not reported other than lethal dose value]

Other Toxicological Information: Intravenous. - Rat LD50: 53 mg/kg [Lungs, Thorax, or Respiration - dyspnea]
Intravenous. - Mouse LD50: 324 mg/kg [Details of toxic effects not reported other than lethal dose value]
Subcutaneous - Rat LDLo: 1700 mg/kg [Sense Organs and Special Senses (Eye) - miosis (pupillary constriction) Behavioral - coma Kidney/Ureter/Bladder - other changes]
Intraperitoneal. - Rat LD50: 400 mg/kg [Details of toxic effects not reported other than lethal dose value]
Intraperitoneal. - Mouse LD50: 650 mg/kg [Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea]
Intraperitoneal. - Rat LDLo: 650 mg/kg [Behavioral - somnolence (general depressed activity) Behavioral - ataxia Lungs, Thorax, or Respiration - respiratory depression]
Intraperitoneal. - Rat TDLo: 514 mg/kg [Behavioral - ataxia]

Mannitol :

RTECS Number: OP2060000

Ingestion: Oral - Rat LD50: 13500 mg/kg [Details of toxic effects not reported other than lethal dose value]
Oral - Mouse LD50: 22 gm/kg [Behavioral - Somnolence (general depressed activity); Gastrointestinal - Ulceration or bleeding from small intestine]

Other Toxicological Information: Intravenous. - Rat LD50: 9690 mg/kg [Details of toxic effects not reported other than lethal dose value]
Intravenous. - Mouse LD50: 7470 mg/kg [Details of toxic effects not reported other than lethal dose value]
Intraperitoneal. - Mouse LD50: 14 gm/kg [Details of toxic effects not reported other than lethal dose value]

SECTION 12 : ECOLOGICAL INFORMATION

Ecotoxicity: No ecotoxicity data was found for the product.

Environmental Stability: No environmental information found for this product.

SECTION 13 : DISPOSAL CONSIDERATIONS

Waste Disposal: Dispose of in accordance with Local, State, Federal and Provincial regulations.

SECTION 14 : TRANSPORT INFORMATION

DOT Shipping Name: Not Regulated.

SECTION 15 : REGULATORY INFORMATION**Famotidine :**

Canada DSL: Listed

L-Aspartic Acid :

TSCA Inventory Status: Listed

EINECS Number: 200-291-6

Canada DSL: Listed

Benzyl Alcohol :

TSCA Inventory Status: Listed

EINECS Number: 202-859-9

Canada DSL: Listed

Canada IDL: Identified under the Canadian Hazardous Products Act Ingredient Disclosure List: 0.1%.169(170)

Mannitol :

TSCA Inventory Status: Listed

EINECS Number: 200-711-8

Canada DSL: Listed

Water for Injection :

TSCA Inventory Status: Listed

Canada DSL: Listed

SECTION 16 : ADDITIONAL INFORMATION**HMIS Ratings:**

HMIS Health Hazard: 1

HMIS Fire Hazard: 1

HMIS Reactivity: 1

HMIS Personal Protection: X

SDS Creation Date: January 08, 2009

SDS Revision Date: June 01, 2015

SDS Format:

Disclaimer:

The information contained herein pertains to this material. It is the responsibility of each individual party to determine for themselves the proper means of handling and using these materials based on their purpose and intended use. Fresenius-Kabi assumes no liability resulting from the use of or reliance upon the information contained in this material safety data sheet. This material safety data sheet does not constitute the guaranty or specifications of the product.

Copyright© 1996-2015 Actio Corporation. All Rights Reserved.